Company Description
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
Company Info
COMPANY ADDRESS
20358 Seneca Meadows Pkwy
Germantown, MD 20876,
United States
COMPANY EMAIL
contact@precigen.com
Latest Precigen News
- A History of Outperforming Analyst Forecasts and Beating the Odds: Precigen Inc (PGEN)
- Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Acorda: PNP to tackle rise in cybercrimes - Inquirer.net
- Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Precigen (NASDAQ:PGEN) Upgraded to Sell by StockNews.com - MarketBeat
- Marcos orders stepped up crackdown on cybercrime – PNP chief - Inquirer.net
- Days-to-cover ratio for PGEN surges to 13.94 due to rise in short interest - Knox Daily
- Top investors say Precigen Inc (PGEN) ticks everything they need - Sete News
- Precigen Inc [PGEN] short interest surges, jumping by 18.84 million million shares
- The growth track for Precigen Inc (PGEN) has changed recently - Sete News